Shanghai Institute of

Company snapshot

Chinese Academy of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Decompensated Cirrhosis, Primary Ovarian Insufficiency. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (2).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shanghai Institute of. Not investment advice.

• What is Shanghai Institute of?

  Chinese Academy of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Decompensated Cirrhosis, Primary Ovarian Insufficiency. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, E

• Is Shanghai Institute of publicly traded?

  Shanghai Institute of appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shanghai Institute of develop or market?

  We link 4 drug profile(s) where Shanghai Institute of is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/chinese-academy-of-sciences#company-drugs.

• What are the latest developments for Shanghai Institute of?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Shanghai Institute of focus on?

  Shanghai Institute of focuses on Decompensated Cirrhosis, Primary Ovarian Insufficiency based on our analysis of their pipeline programs and drug development activities.